When was Ardelyx founded?

Ardelyx was founded in 2007 and raised its 1st funding round 1 year after it was founded.

Where is Ardelyx located?

Ardelyx is headquartered in Fremont, United States. It is registered at Fremont, California.

How many employees does Ardelyx have?

As of Apr 30, 2026, the latest employee count at Ardelyx is 494.

Is Ardelyx a funded company?

Ardelyx is a funded company, having raised a total of $61.1M across 8 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 2008.

When was the latest funding round of Ardelyx?

Ardelyx's latest funding was a $***** Post IPO round on Jun 30, 2022, with participation from 1 investor.

What is the annual revenue of Ardelyx?

Annual revenue of Ardelyx is $407M as on Dec 31, 2025.

Where does Ardelyx rank among its competitors?

Ardelyx ranks 3rd amongst 122 active competitors, of which 40 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Helex, which secured $3.5M in Oct, 2025.

Who are the top competitors of Ardelyx?

Ardelyx's top competitors include Aurinia Pharmaceuticals, Akebia Therapeutics and Alchemab. Among them, Helex secured the most recent funding round in October, 2025.

Ardelyx - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases. Its lead product, Tenapanor (RDX5791), a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and hyperphosphatemia in chronic kidney disease patients on dialysis. Also developing RDX002, treatment of high potassium, or hyperkalemia, in kidney and heart disease patients.

Website: ardelyx.com
Email ID: *****@ardelyx.com
Registered Address: Fremont, California

Key Metrics

Founded Year

2007

Location

Fremont, United States

Stage

Public

Total Funding

$61.1M in 8 rounds

Latest Funding Round

Post IPO, Jun 30, 2022, $*****

Investors

New Enterprise Associates & 12 more

Ranked

3^rd among 122 active competitors

Annual Revenue

$407M as on Dec 31, 2025

Employee Count

494 as on Apr 30, 2026

Similar Companies

Akebia Therapeutics & 52 more

Exit Details

Public

View Ardelyx's full profile

Ardelyx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ardelyx, Inc. CIN: 261303944 , United States, Active	Dec 26, 999	$407M (As on Dec 31, 2025)	398 (As on Dec 31, 2024)	-

Ardelyx got listed on Jun 19, 2014.

Click here to take a look at Ardelyx's IPO in detail

Ardelyx has raised a total funding of $61.1M over 8 rounds. Its first funding round was on Jun 2008. Its latest funding round was a Post IPO round on Jun 30, 2022 for $*****. 1 investor participated in its latest round. Ardelyx has 13 institutional investors.

Here is the list of recent funding rounds of Ardelyx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 30, 2022	6745222	Post IPO	9343566	2936747	1874761	1350204
Nov 25, 2019	8881137	Post IPO	1918084	5536949	6836777	Kyowa Kirin
May 16, 2018	8208519	Conventional Debt	4455079	9661012	9895354	SLR Investment Corp & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Ardelyx's funding rounds and investors

The founders of Ardelyx is Peter G Schultz. Mike Raab is the CEO of Ardelyx.

Here are the details of Ardelyx's key team members:

Peter G Schultz: Co-Founder of Ardelyx and founder of 1 other company.

View details of Ardelyx's Founder profiles and Board Members

Ardelyx's employee count trend

Ardelyx has 494 employees as of Apr 26. Here is Ardelyx's employee count trend over the years:

Uncover Ardelyx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ardelyx include Aurinia Pharmaceuticals, Akebia Therapeutics and Alchemab. Here is the list of Top 10 competitors of Ardelyx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	RA Capital Management, Redmile Group & 10 others	67/100
2nd	Akebia Therapeutics 2007, Cincinnati (United States), Public	Developing therapeutics solutions to treat patients with kidney disease	$91M	Genechem, Orchard Venture Partners & 13 others	66/100
3rd	Ardelyx 2007, Fremont (United States), Public	Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases	$61.1M	RA Capital Management, Western Alliance Bank ... & 11 others	65/100
4th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$115M	RA Capital Management, SV Health Investors ... & 13 others	64/100
5th	Enyo Pharma 2014, Lyon (France), Series C	Developer of therapeutics for diseases with impaired kidney function	$120M	Orbimed, Morningside & 9 others	62/100
6th	Arthrosi Therapeutics 2017, Irvine (United States), Acquired	Developer of therapeutics for gout, chronic kidney diseases, and oncology	$293M	Prime Eight Capital, Guangrun Health Industry ... & 11 others	61/100
7th	Renalys 2023, Chuo City (Japan), Acquired	Developer of therapeutics for the treatment of renal diseases	$38.2M	SR One, Catalys Pacific & 4 others	61/100
8th	Alebund 2018, Shanghai (China), Series B	Developer of therapeutics for kidney diseases	$114M	Morningside, 3H Health Investment & 14 others	60/100
9th	Calliditas Therapeutics 2004, Stockholm (Sweden), Public	Provider of small molecule based drug for inflammatory kidney disease	$44.8M	Investinor, Athyrium Capital Management & 3 others	59/100
10th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	pi Ventures, IndieBio & 2 others	59/100